ClinicalTrials.gg
CompletedNCT00191269Updated Mar 17, 2010Results posted

Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen

A Phase 2 interventional study of gemcitabine and gemcitabine in Metastatic Breast Cancer, sponsored by Eli Lilly and Company. Completed at 13 sites in Japan. Open to female participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2010-03-17.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Non-randomized
Ages
20 Years to 74 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.

Enrollment
45th of 90
68 · median 68
Started
2005
with 4 others
Phase 2
65 of 95
none open now
Registered
22nd of 95
by date
Lead sponsor
20 of 95
Eli Lilly and Company

Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 45th largest by enrollment of the 90 interventional ones that give a count, is one of 5 that started in 2005, is one of 65 in phase 2, and was the 22nd registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 20 Years to 74 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing gemcitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

To investigate efficacy, safety and PK of GEM monotherapy after prior chemotherapy with anthracycline and taxane regimen for patients with metastatic breast cancer

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • after
  • anthracycline
  • taxane
  • regimen
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • and/or cytologically confirmed breast cancer
  • Received prior chemotherapy for breast cancer with anthracycline and taxane regimen
  • To have at least one measurable region
  • PS: 0-1
  • To have adequate organ function (bone marrow, liver and renal function)

Exclusion criteria

Exclusion Criteria:

  • To have Interstitial pneumonia or pulmonary fibrosis
  • To have inflammatory carcinoma
  • Within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest hormonal/immunotherapy or 7 days after surgery
  • To have with symptom
  • To have severe complication (cardiac infarction, infection, drug hyper sensitivity or diabetes)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    A

    Dose Level 1 - 1000 mg/m2

    Drug: gemcitabine

  • Experimental
    B

    Dose Level 2 - 1250 mg/m2

    Drug: gemcitabine

Interventions

  • 1000 mg/m2, intravenous (IV), day 1 and day 8 every 21 days

    Also known as: LY188011, Gemzar

  • 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days

    Also known as: LY188011, Gemzar

06

What researchers measure

Primary outcomes

  1. Tumor Response

    Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.

    Time frame: baseline to measured progressive disease

Secondary outcomes

  1. Duration of Response

    For responders, the minimum and maximum of the duration of complete response, duration of partial response, and duration of overall response were summarized, and the median of response duration and its 95% confidence interval were calculated using the Kaplan-Meier estimation.

    Time frame: time of response to progressive disease

  2. Time to Progressive Disease

    Time from study enrollment to first date of disease progression. Time to disease progression was censored at date of death if death was due to other cause. The minimum and maximum of this parameter were summarized, and the median time to progression and its 95% confidence interval were calculated using the Kaplan-Meier estimation.

    Time frame: baseline to measured progressive disease

  3. Survival at 1 Year

    Results are reported as number of participants alive at one year.

    Time frame: baseline to date of death from any cause, evaluate at 1 year

  4. Pharmacokinetics - Normalized Cmax

    maximum gemcitabine plasma concentration normalized to 1250 milligrams per square meter of gemcitabine.

    Time frame: cycle 1

  5. Pharmacokinetics - Normalized Area Under the Curve

    Area under the gemcitabine plasma concentration-time curve from time zero to infinity. Gemcitabine dose was normalized to 1250 milligrams per square meter.

    Time frame: cycle 1

07

Results

Posted May 14, 2009

Participant flow

Participant flow — Overall Study
MilestoneDose Level 1Dose Level 2
Started662
Completed04
Not completed658
Withdrew: Protocol violation02
Withdrew: Adverse event14
Withdrew: Progression of disease442
Withdrew: Lack of efficacy15
Withdrew: Withdrawal by subject01
Withdrew: Pathologic aggrevation01
Withdrew: Physician decision03

Outcome measures

PrimaryTumor Response

Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.

Time frame:
baseline to measured progressive disease
Reported as:
Number · participants
Tumor Response
participantsDose Level 1Dose Level 2
Complete Response01
Partial Response04
Long Stable Disease14
Stable Disease116
Progressive Disease232
Not Evaluable25
SecondaryDuration of Response

For responders, the minimum and maximum of the duration of complete response, duration of partial response, and duration of overall response were summarized, and the median of response duration and its 95% confidence interval were calculated using the Kaplan-Meier estimation.

Time frame:
time of response to progressive disease
Reported as:
Median · months
Duration of Response
monthsDose Level 1Dose Level 2
Duration of Response—10.07 (5.43 to 13.80)
SecondaryTime to Progressive Disease

Time from study enrollment to first date of disease progression. Time to disease progression was censored at date of death if death was due to other cause. The minimum and maximum of this parameter were summarized, and the median time to progression and its 95% confidence interval were calculated using the Kaplan-Meier estimation.

Time frame:
baseline to measured progressive disease
Reported as:
Median · days
Time to Progressive Disease
daysDose Level 1Dose Level 2
Time to Progressive Disease137 (97 to 196)92 (78 to 121)
SecondarySurvival at 1 Year

Results are reported as number of participants alive at one year.

Time frame:
baseline to date of death from any cause, evaluate at 1 year
Reported as:
Number · participants
Survival at 1 Year
participantsDose Level 1Dose Level 2
Survival at 1 Year442
SecondaryPharmacokinetics - Normalized Cmax

maximum gemcitabine plasma concentration normalized to 1250 milligrams per square meter of gemcitabine.

Time frame:
cycle 1
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics - Normalized Cmax
nanograms per milliliter (ng/mL)Dose Normalized to 1250 Milligrams Per Square Meter
Pharmacokinetics - Normalized Cmax29,036 (16,341 to 53,857)
SecondaryPharmacokinetics - Normalized Area Under the Curve

Area under the gemcitabine plasma concentration-time curve from time zero to infinity. Gemcitabine dose was normalized to 1250 milligrams per square meter.

Time frame:
cycle 1
Reported as:
Geometric mean · nanograms times hour per milliliter
Pharmacokinetics - Normalized Area Under the Curve
nanograms times hour per milliliterDose Normalized to 1250 Milligrams Per Square Meter
Pharmacokinetics - Normalized Area Under the Curve15,999 (9,929 to 21,723)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level 1———
Dose Level 2———
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventDose Level 1Dose Level 2
DyspnoeaRespiratory, thoracic and mediastinal disorders1/60/62
CellulitisInfections and infestations1/61/62
Catheterisation venousSurgical and medical procedures0/62/62
Blood lactate dehydrogenase increasedInvestigations0/61/62
InfectionInfections and infestations0/61/62
Femur fractureMusculoskeletal and connective tissue disorders0/61/62
Cardiac failure acuteCardiac disorders0/61/62
AnorexiaMetabolism and nutrition disorders0/61/62
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/61/62
Brain oedemaNervous system disorders0/61/62
Most frequent other events
Showing 10 of 15
Most frequent other events
EventDose Level 1Dose Level 2
Neutrophil count decreasedInvestigations2/626/62
Alanine aminotransferase increasedInvestigations1/68/62
AnorexiaMetabolism and nutrition disorders1/61/62
Aspartate aminotransferase increasedInvestigations0/64/62
NauseaGastrointestinal disorders0/63/62
VomitingGastrointestinal disorders0/63/62
MalaiseGeneral disorders0/61/62
PyrexiaGeneral disorders0/61/62
NasopharyngitisInfections and infestations0/61/62
C-reactive protein increasedInvestigations0/61/62

Baseline characteristics

Age Continuous
Age Continuous(years)Dose Level 1Dose Level 2Total
Mean53.3 ± 7.4552.4 ± 11.2552.5 ± 10.93
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level 1Dose Level 2Total
Female66268.0
Male000.0
Region of Enrollment
Region of Enrollment(participants)Dose Level 1Dose Level 2Total
Japan66268.0
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Dose Level 1Dose Level 2Total
0 - Fully Active44549.0
1 - Ambulatory, Restricted Strenuous Activity21719.0
Human Epidermal Growth Factor Receptor 2 Expression Status
Human Epidermal Growth Factor Receptor 2 Expression Status(participants)Dose Level 1Dose Level 2Total
022729.0
1+12021.0
2+246.0
3+1910.0
Unknown022.0
Presence of Estrogen Hormone Receptor
Presence of Estrogen Hormone Receptor(participants)Dose Level 1Dose Level 2Total
None42529.0
Present23739.0
Unknown000.0
Presence of Metastasis
Presence of Metastasis(participants)Dose Level 1Dose Level 2Total
None055.0
Lung02727.0
Bone12425.0
Liver22527.0
Brain000.0
Lymph Node22325.0
Skin167.0
Other Sites01313.0
Presence of Progesterone Hormone Receptor
Presence of Progesterone Hormone Receptor(participant)Dose Level 1Dose Level 2Total
None33942.0
Present22325.0
Unknown101.0

4 further baseline measures are reported on the registry.

08

Study locations

13 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aichi, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ehime, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukushima, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gunma, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyogo, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kumamoto, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Niigata, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saitama, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Mar 2008 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Jun 2005
Primary completionActual
Mar 2008
CompletionActual
Mar 2010
Results first posted
May 14, 2009
Last update
Mar 17, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00191269
First posted
Sep 19, 2005
Start date
Jun 2005
Primary completion
Mar 2008
Completion
Mar 2010
Results posted
May 14, 2009
Last update
Mar 17, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine

Start the discussion